TNGX
Tango Therapeutics, Inc.
$23.02
-1.96%
2026-05-08
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-14.30
EPS (TTM)
$-0.87
ROE
-37.2%
Revenue Growth (YoY)
-100.0%
Profit Margin
-162.9%
Debt/Equity
9.70
Price/Book
9.16
Beta
1.22
Market Cap
$3.36B
Avg Volume (10D)
3.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$28.41
60D Low
$10.80
Avg Volume
3.3M
Latest Close
$23.02
Get breakout alerts for TNGX
Sign up for Breakout Scanner to receive daily notifications when TNGX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Tango Therapeutics, Inc. (TNGX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TNGX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TNGX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.